Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan-Reference-Cited by-同舟云学术

Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan

Published:2023-09-07 Issue: Volume: Page:1-13
ISSN:0020-7454
Container-title:International Journal of Neuroscience
language:en
Short-container-title:International Journal of Neuroscience

Author:

Tachibana Yosuke¹^ORCID,Sato Ryusuke¹^ORCID,Makioka Haruki¹^ORCID,Hoshino Misuzu¹^ORCID,Jin Mingshou¹^ORCID

Affiliation:

1. Biogen Japan, Tokyo, Japan

Funder

Biogen Japan

Publisher

Informa UK Limited

Subject

General Medicine,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/00207454.2023.2251662

Reference33 articles.

1. Spinal muscular atrophy

2. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity

3. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model

4. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

5. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy;Journal of Neurology;2024-09-06

2. Clinical perspectives: Treating spinal muscular atrophy;Molecular Therapy;2024-08

3. Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy;Arquivos de Neuro-Psiquiatria;2024-01